Home › Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
 

Keywords :   


Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement

2013-02-20 13:00:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. & SEOUL, South Korea WHITEHOUSE STATION, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. Language:  English Contact HTML:  Merck Media Relations:Ronald Rogers, 908-423-6449orMerck Investor Relations:Justin Holko, 908-423-5088orSamsung Bioepis:HongSeok Ji, +82-32-455-6102 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: enter development agreement samsung

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
04.11Natracare Launches E-Commerce Site
04.11Tropical Depression Eighteen Graphics
04.11The Honey Pot Launches Witch Hazel Intimate Wash & Wipes
04.11Remnants of Patty Graphics
04.11Tropical Depression Eighteen Forecast Discussion Number 4
04.11Remnants of Patty Forecast Discussion Number 10
More »